In 2025, AbbVie’s presentation focused on its efforts to build-up its pipeline of early-stage assets. This was part of the company’s plans to move forward from the loss of Humira, one of its key products.

2025

Around the same time as the JP Morgan conference, AbbVie announced an update to its ABBV-RGX 314 clinical program exploring the effectiveness of gene therapy delivery methods for treatments involving the eyes.

In a press release issued at the time,¹ AbbVie’s vice president and global head of ophthalmology clinical development Michael Robinson, MD, said, “Retinal diseases are progressive, with wet AMD and DR among the leading causes of blindness. More treatment options are needed to help relieve the current treatment burden of chronic, frequent dosing. We are excited to continue moving closer to our goal of delivering an additional treatment option to patients with wet AMD and DR in hopes of addressing their significant unmet needs."

In the same press release, REGENXBIO president and chief executive officer Curran Simpson said, “ABBV-RGX-314 has the potential to help millions of people living with wet AMD and DR, globally, who are facing these debilitating diseases. Together with AbbVie, we are excited to continue developing ABBV-RGX-314 as the first potential one-time gene therapy for wet AMD and DR."

2024

In 2024, AbbVie’s presentation at the conference focused on its recent acquisitions of ImmunoGen and Cerevel. AbbVie paid about $10.1 billion for the former company and about $8.7 billion for the latter.

In a press release announcing the ImmunoGen acquisition,² AbbVie’s chairman and chief executive officer Richard A. Gonzalex said, “The acquisition of ImmunoGen demonstrates our commitment to deliver on our long-term growth strategy and enables AbbVie to further diversify our oncology pipeline across solid tumors and hematologic malignancies. Together, AbbVie and ImmunoGen have the potential to transform the standard of care for people living with cancer."

In the same press release, ImmunoGen’s president and chief executive officer Mark Enyedy added, “With global commercial infrastructure and deep clinical and regulatory expertise, AbbVie is the right company to accelerate geographic and label expansion, and realize the full potential of ELAHERE as the first and only ADC approved in ovarian cancer. The addition of ImmunoGen's pipeline, platform, and expertise to AbbVie's oncology portfolio is an exciting opportunity for the combined companies to advance innovation in ADCs. This transaction is the culmination of our 40-year commitment to develop and deliver the next-generation of ADCs and more good days for people living with cancer."

In the Cerevel Therapeutics announcement,³ Gonzalez said, “Our existing neuroscience portfolio and our combined pipeline with Cerevel represents a significant growth opportunity well into the next decade. AbbVie will leverage its deep commercial capabilities, international infrastructure, and regulatory and clinical expertise to deliver substantial shareholder value with multibillion-dollar sales potential across Cerevel's portfolio of assets."

Cerevel Therapeutics president and chief executive officer Ron Renaud added, “Cerevel has always been committed to transforming what is possible in neuroscience. With AbbVie's long-standing expertise in developing and commercializing medicines on a global scale, Cerevel's novel therapies will be well positioned to reach more people living with neuroscience diseases. The talented, passionate, and dedicated Cerevel team has made great progress over the past five years in developing our innovative suite of potential medicines, and we are pleased that AbbVie has recognized the tremendous potential of our pipeline. This acquisition reinforces the renaissance we are seeing in neuroscience, and we are proud to be at the forefront."

Sources

1. AbbVie and Regenxbio Announce Updates on the ABBV-RGX 314 Clinical Program. AbbVie. January 13, 2025. Accessed December 12, 2025. https://news.abbvie.com/2025-01-13-AbbVie-and-REGENXBIO-Announce-Updates-on-the-ABBV-RGX-314-Clinical-Program
2. AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio. AbbVie. November 30, 2023. Accessed December 12, 2025. https://news.abbvie.com/2023-11-30-AbbVie-to-Acquire-ImmunoGen,-including-its-Flagship-Cancer-Therapy-ELAHERE-R-mirvetuximab-soravtansine-gynx-,-Expanding-Solid-Tumor-Portfolio
3. AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline. AbbVie. December 6, 2023. Accessed December 12, 2025. https://news.abbvie.com/2023-12-06-AbbVie-to-Acquire-Cerevel-Therapeutics-in-Transformative-Transaction-to-Strengthen-Neuroscience-Pipeline